<DOC>
	<DOC>NCT00423241</DOC>
	<brief_summary>This study will compare the clinical performance of the SEMPERFLO* Pain Management System with another commercial pain relief system using 0.5% bupivacaine following unilateral, open, inguinal hernia repair procedures. *Trademark</brief_summary>
	<brief_title>SEMPERFLO* Pain Management System in Inguinal Hernia Repair</brief_title>
	<detailed_description>Pain will be evaluated up to 5 days after surgery Subjects will be followed for 30 days after surgery.</detailed_description>
	<mesh_term>Hernia</mesh_term>
	<mesh_term>Hernia, Inguinal</mesh_term>
	<criteria>Subject is a candidate for primary, nonemergent unilateral, open inguinal hernia repair procedure Subject is 18 years or older Subject must be willing to participate in the study, and provide informed consent to participate. Subjects undergoing recurrent hernia repair; Subjects who plan to undergo another elective surgical procedure prior to the completion of this study; Subjects with known allergy to bupivacaine; Subjects with immunodeficiency diseases (including known HIV); Subjects with any findings identified by the surgeon that may preclude conduct of the study; Subjects who are known current alcohol and/or drug abusers;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>